Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

MyStart Health vs Queen RX

MyStart Health
Graded #168

Higher grade

vs+0.7999999999999972
Queen RX
Graded #192

Lower grade

The verdict

MyStart Health takes it — 67.1/100 to 66.3/100, but only just.

MyStart Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. MyStart Health offers all-inclusive compounded semaglutide and tirzepatide at $299/month with a price-lock guarantee, same-day physician consultations, and 24/7 care team access. Queen RX is close behind and may still be the better fit — see the factor split below.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueQueen RX +29
48
77
Dose & formulationMyStart Health +26
83
57
Clinical oversightMyStart Health +15
84
69
Labs & monitoringMyStart Health +13
66
53
FulfillmentMyStart Health +3
78
75
Contract termsQueen RX +30
31
61
MyStart Health · left barQueen RX · right bar

The numbers

MetricMyStart HealthQueen RX
WeighScore67.1/10066.3/100
GradeCC
Scorecard rank#168#192
Semaglutide$299/mo (all doses, compounded)$100/mo (quarterly plan, compounded)
Tirzepatide$299/mo (all doses, compounded)Not disclosed
CoverageCoverage not published45 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualYesInjection only
MyStart Health

Graded #168 · C

Strengths

  • Price Lock Guarantee — your $299 base rate doesn't rise as your dose escalates
  • Fast onboarding: roughly 5-minute intake, 24-hour prescription turnaround, 2–4 day shipping
  • 24/7 care team access with unlimited clinician messaging included
  • LegitScript certified
  • Clear Section 503A compounding disclosure on every landing page

Where it loses points

  • Not BBB accredited — C+ rating with 10 complaints, mostly shipping delays and support access
  • Compounded only — no FDA-approved Ozempic, Wegovy, Zepbound, or Mounjaro
  • Markets oral tirzepatide, but no FDA-approved oral tirzepatide exists
  • Very new company (incorporated May 2024) with a limited track record
  • Pharmacy partners not named, so 503A compliance can't be independently verified
Queen RX

Graded #192 · C

Strengths

  • $299/quarter (~$100/mo) — among the lowest GLP-1 pricing in the dataset
  • Three GLP-1 options: semaglutide, tirzepatide, and liraglutide
  • 45-state coverage

Where it loses points

  • No LegitScript or PCAB accreditation
  • No legal entity name or address disclosed
  • No named pharmacy partners
  • Not available in KS, LA, MS, NM, WV

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard